These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38841103)

  • 21. Efficacy and safety of hypoglycemic drugs in improving cognitive function in patients with Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis.
    Wang XC; Chu CL; Li HC; Lu K; Liu CJ; Cai YF; Quan SJ; Zhang SJ
    Front Neurol; 2022; 13():1018027. PubMed ID: 36530613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcranial magnetic stimulation effects on cognitive enhancement in mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis.
    Yan Y; Tian M; Wang T; Wang X; Wang Y; Shi J
    Front Neurol; 2023; 14():1209205. PubMed ID: 37528850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
    Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
    Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory markers in Alzheimer's disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies.
    Shen XN; Niu LD; Wang YJ; Cao XP; Liu Q; Tan L; Zhang C; Yu JT
    J Neurol Neurosurg Psychiatry; 2019 May; 90(5):590-598. PubMed ID: 30630955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The sTREM2 Concentrations in the Blood: A Marker of Neurodegeneration?
    Ferri E; Rossi PD; Geraci A; Ciccone S; Cesari M; Arosio B
    Front Mol Biosci; 2020; 7():627931. PubMed ID: 33768114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration.
    Franzmeier N; Suárez-Calvet M; Frontzkowski L; Moore A; Hohman TJ; Morenas-Rodriguez E; Nuscher B; Shaw L; Trojanowski JQ; Dichgans M; Kleinberger G; Haass C; Ewers M;
    Mol Neurodegener; 2020 Oct; 15(1):57. PubMed ID: 33032659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
    Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
    Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P-tau231 as a Diagnostic Biomarker for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.
    Nabizadeh F; Salehi N; Ramezannezhad E; Sadeghmousavi S; Khalili E
    Ann Indian Acad Neurol; 2022; 25(5):845-851. PubMed ID: 36560987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.
    Ashton NJ; Suárez-Calvet M; Heslegrave A; Hye A; Razquin C; Pastor P; Sanchez-Valle R; Molinuevo JL; Visser PJ; Blennow K; Hodges AK; Zetterberg H
    Alzheimers Res Ther; 2019 Nov; 11(1):94. PubMed ID: 31779670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
    Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
    Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-Analysis of Neurochemical Changes Estimated via Magnetic Resonance Spectroscopy in Mild Cognitive Impairment and Alzheimer's Disease.
    Liu H; Zhang D; Lin H; Zhang Q; Zheng L; Zheng Y; Yin X; Li Z; Liang S; Huang S
    Front Aging Neurosci; 2021; 13():738971. PubMed ID: 34744689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemokines in patients with Alzheimer's disease: A meta-analysis.
    Wang H; Zong Y; Zhu L; Wang W; Han Y
    Front Aging Neurosci; 2023; 15():1047810. PubMed ID: 36967827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum.
    Rauchmann BS; Schneider-Axmann T; Alexopoulos P; Perneczky R;
    Neurobiol Aging; 2019 Feb; 74():182-190. PubMed ID: 30458365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease.
    Edwin TH; Henjum K; Nilsson LNG; Watne LO; Persson K; Eldholm RS; Saltvedt I; Halaas NB; Selbæk G; Engedal K; Strand BH; Knapskog AB
    Alzheimers Dement (Amst); 2020; 12(1):e12128. PubMed ID: 33313376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does Soluble TREM2 Protect Against Alzheimer's Disease?
    Brown GC; St George-Hyslop P
    Front Aging Neurosci; 2021; 13():834697. PubMed ID: 35153729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glial activation and inflammation along the Alzheimer's disease continuum.
    Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
    J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.
    Suárez-Calvet M; Kleinberger G; Araque Caballero MÁ; Brendel M; Rominger A; Alcolea D; Fortea J; Lleó A; Blesa R; Gispert JD; Sánchez-Valle R; Antonell A; Rami L; Molinuevo JL; Brosseron F; Traschütz A; Heneka MT; Struyfs H; Engelborghs S; Sleegers K; Van Broeckhoven C; Zetterberg H; Nellgård B; Blennow K; Crispin A; Ewers M; Haass C
    EMBO Mol Med; 2016 May; 8(5):466-76. PubMed ID: 26941262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer's disease.
    Wang ZB; Ma YH; Sun Y; Tan L; Wang HF; Yu JT;
    J Neuroinflammation; 2022 Dec; 19(1):316. PubMed ID: 36578067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological correlates of elevated soluble TREM2 in cerebrospinal fluid.
    Winfree RL; Dumitrescu L; Blennow K; Zetterberg H; Gifford KA; Pechman KR; Jefferson AL; Hohman TJ;
    Neurobiol Aging; 2022 Oct; 118():88-98. PubMed ID: 35908327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral sTREM2-Related Inflammatory Activity Alterations in Early-Stage Alzheimer's Disease.
    Weber GE; Khrestian M; Tuason ED; Shao Y; Pillai J; Rao S; Feng H; Zhou Y; Cheng F; DeSilva TM; Stauffer S; Leverenz JB; Bekris LM
    J Immunol; 2022 May; 208(10):2283-2299. PubMed ID: 35523454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.